Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma Review


Authors: Lesokhin, A. M.; Bal, S.; Badros, A. Z.
Review Title: Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma
Abstract: Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignancy of terminally differentiated plasma cells, PD-1 pathway blockade is ineffective as a single agent. The initial promise in combination approaches utilizing anti–PD-1 with the immunomodulatory drugs, lenalidomide or pomalidomide, was not confirmed in randomized trials. Here, we explore available data for and against manipulation of the PD-1 pathway and other immune checkpoints in myeloma and highlight several promising concepts and challenges that face ongoing development of immunotherapeutics for this disease. © 2019 American Association for Cancer Research.
Journal Title: Cancer Immunology Research
Volume: 7
Issue: 8
ISSN: 2326-6066
Publisher: American Association for Cancer Research  
Date Published: 2019-08-01
Start Page: 1224
End Page: 1229
Language: English
DOI: 10.1158/2326-6066.Cir-19-0148
PUBMED: 31371317
PROVIDER: scopus
PMCID: PMC6891823
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alexander Meyer Lesokhin
    363 Lesokhin
  2. Susan Bal
    13 Bal